|
US5270163A
(en)
|
1990-06-11 |
1993-12-14 |
University Research Corporation |
Methods for identifying nucleic acid ligands
|
|
US6140490A
(en)
|
1996-02-01 |
2000-10-31 |
Nexstar Pharmaceuticals, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
|
ES2259800T3
(es)
|
1990-06-11 |
2006-10-16 |
Gilead Sciences, Inc. |
Procedimientos de uso de ligandos de acido nucleico.
|
|
AU7808198A
(en)
|
1997-06-03 |
1998-12-21 |
Biocryst Pharmaceuticals, Inc. |
Novel compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
|
|
NZ503033A
(en)
|
1997-08-26 |
2003-01-31 |
Gliatech Inc |
Inhibition of complement activation using anti-properdin agents
|
|
AU1252099A
(en)
|
1997-11-26 |
1999-06-15 |
Medical Research Council |
Improved selex procedure and an anti-cd4 aptamer
|
|
US6956107B2
(en)
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
|
US7112327B2
(en)
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
|
GB9930659D0
(en)
|
1999-12-24 |
2000-02-16 |
Bio Discovery Ltd |
Inhibitors of complement activation
|
|
US6998468B2
(en)
|
2000-03-23 |
2006-02-14 |
Tanox, Inc. |
Anti-C2/C2a inhibitors of complement activation
|
|
WO2004075838A2
(en)
|
2003-02-21 |
2004-09-10 |
Rikshospitalet-Radiumhospitalet Hf |
Method and compositions for the treatment of meconium aspiration syndrome
|
|
BRPI0506629A
(pt)
|
2004-02-10 |
2007-05-02 |
Univ Colorado |
inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
EP1861114B1
(en)
|
2005-03-11 |
2011-02-02 |
Potentia Pharmaceuticals, Inc. |
Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration
|
|
WO2006128006A1
(en)
|
2005-05-26 |
2006-11-30 |
The Regents Of The University Of Colorado |
Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
|
|
US8168584B2
(en)
*
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
|
JP5219819B2
(ja)
|
2005-10-21 |
2013-06-26 |
カタリスト・バイオサイエンシーズ・インコーポレイテッド |
補体活性化を阻害する修飾プロテアーゼ
|
|
SG10201804008UA
(en)
|
2005-11-04 |
2018-06-28 |
Genentech Inc |
Use of complement pathway inhibitors to treat ocular diseases
|
|
AU2006337093B2
(en)
|
2005-12-22 |
2013-03-14 |
Opko Pharmaceuticals, Llc. |
Compositions and methods for regulating complement system
|
|
KR20080087814A
(ko)
|
2005-12-22 |
2008-10-01 |
알콘 리서치, 리미티드 |
보체 인자 ｈ의 위험 변이체가 있는 환자에서 연령 관련황반변성의 예방 및 치료를 위한 ｃ3-전환효소 저해제
|
|
US20070196367A1
(en)
|
2006-02-22 |
2007-08-23 |
Valentin Dinu |
Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
|
|
NZ571791A
(en)
|
2006-03-08 |
2012-03-30 |
Archemix Llc |
Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
|
|
EP2073898A1
(en)
|
2006-10-10 |
2009-07-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Complement inhibition for improved nerve regeneration
|
|
US8790924B2
(en)
|
2006-10-19 |
2014-07-29 |
Duke University |
Reversible platelet inhibition
|
|
TW201716437A
(zh)
|
2006-11-02 |
2017-05-16 |
建南德克公司 |
人類化之抗-因子ｄ抗體及其用途
|
|
HUE026001T2
(en)
|
2007-02-05 |
2016-04-28 |
Apellis Pharmaceuticals Inc |
Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
|
|
CA2680833A1
(en)
*
|
2007-04-30 |
2008-11-13 |
Alcon Research, Ltd. |
Treatment of age-related macular degeneration using inhibitors of complement factor d
|
|
AR066660A1
(es)
*
|
2007-05-23 |
2009-09-02 |
Genentech Inc |
Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
|
|
US20090092980A1
(en)
|
2007-07-20 |
2009-04-09 |
Christoph Arenz |
miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES
|
|
CN101970002B
(zh)
|
2007-08-27 |
2016-05-18 |
诺福麦德治疗学股份有限公司 |
用因子Bb特异性抗体抑制补体活化的方法
|
|
GB0718737D0
(en)
|
2007-09-25 |
2007-11-07 |
Glaxo Group Ltd |
Antibodies
|
|
US8921523B2
(en)
|
2007-12-11 |
2014-12-30 |
Glaxo Group Limited |
Humanized anti-beta-amyloid antibodies
|
|
AU2009215846B2
(en)
|
2008-02-19 |
2014-08-14 |
The Trustees Of The University Of Pennsylvania |
Complement inhibitors as therapeutic agents for treatment of cancer
|
|
US8940299B2
(en)
|
2008-02-28 |
2015-01-27 |
Case Western Reserve University |
Method of treating cancer
|
|
US8664362B2
(en)
|
2008-03-03 |
2014-03-04 |
NovelMed Therapeutics |
Humanized and chimeric anti-properdin antibodies
|
|
DK2262831T3
(en)
|
2008-03-03 |
2015-04-27 |
Novelmed Therapeutics Inc |
ANTI-Properdin ANTIBODIES
|
|
US20110190221A1
(en)
|
2008-03-28 |
2011-08-04 |
Apellis Ag |
Modulation and repletion/enhancement of the complement system for treatment of trauma
|
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
|
EP2159286A1
(en)
|
2008-09-01 |
2010-03-03 |
Consiglio Nazionale Delle Ricerche |
Method for obtaining oligonucleotide aptamers and uses thereof
|
|
US20110160636A1
(en)
|
2008-09-10 |
2011-06-30 |
Rekha Bansal |
Device and method for inhibiting complement activation
|
|
GB0904427D0
(en)
*
|
2009-03-13 |
2009-04-29 |
Lachmann Peter |
Treatment of diseases related to hyperactivity of the complement system
|
|
AU2010248380B2
(en)
|
2009-05-15 |
2013-12-19 |
Nec Solution Innovators, Ltd. |
Aptamer that recognizes peptide
|
|
WO2011003098A1
(en)
|
2009-07-02 |
2011-01-06 |
Musc Foundation For Research Development |
Methods of stimulating liver regeneration
|
|
EP2455469A4
(en)
|
2009-07-16 |
2013-03-13 |
Nec Software Ltd |
FOR BINDING TO HMGB1 ABLE NUCLEIC ACID MOLECULE AND USE THEREOF
|
|
US20120190578A1
(en)
|
2009-08-06 |
2012-07-26 |
Washington University |
Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes
|
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
|
BR112013010769A2
(pt)
|
2010-11-01 |
2019-09-24 |
Genentech Inc |
predição de progressão para degeneração macular relacionada à idade avançada usando um escore poligênico
|
|
PT2661433T
(pt)
|
2011-01-04 |
2017-10-24 |
Novartis Ag |
Compostos de indole ou seus análogos úteis para o tratamento da degeneração macular relacionada com a idade (amd)
|
|
EP3524258B1
(en)
|
2011-06-22 |
2025-10-01 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
|
US10966945B2
(en)
|
2011-08-01 |
2021-04-06 |
Aurin Biotech Inc. |
Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic synthetic complex
|
|
RU2633510C2
(ru)
|
2011-09-28 |
2017-10-12 |
Рибомик Инк. |
Аптамер против ngf и его применение
|
|
US9316647B2
(en)
|
2011-12-30 |
2016-04-19 |
Somalogic, Inc. |
Aptamers and diagnostic methods for detecting the EGF receptor
|
|
RU2662932C2
(ru)
|
2013-03-14 |
2018-07-31 |
Карибо Биосайенсиз, Инк. |
Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты
|
|
SG11201601044XA
(en)
|
2013-08-12 |
2016-03-30 |
Genentech Inc |
Compositions and method for treating complement-associated conditions
|
|
US20150104445A1
(en)
|
2013-10-10 |
2015-04-16 |
Viropharma Holdings Limited |
Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
|
|
US9732103B2
(en)
|
2014-02-25 |
2017-08-15 |
Achillion Pharmaceuticals, Inc. |
Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
|
|
AU2015253042A1
(en)
*
|
2014-05-01 |
2016-10-20 |
Genentech, Inc. |
Anti-factor D antibody variants and uses thereof
|
|
TWI623617B
(zh)
|
2014-08-29 |
2018-05-11 |
國立清華大學 |
對卵巢癌具有專一性之適合體及其應用
|
|
US20180356408A1
(en)
|
2015-11-19 |
2018-12-13 |
Base Pair Biotechnologies, Inc. |
Methods and materials for sensitive detection of target molecules
|
|
WO2017127761A1
(en)
|
2016-01-20 |
2017-07-27 |
Vitrisa Therapeutics, Inc. |
Compositions and methods for inhibiting factor d
|
|
WO2017127762A1
(en)
|
2016-01-20 |
2017-07-27 |
Vitrisa Therapeutics, Inc. |
Methods for improved aptamer selection
|
|
AU2017217677A1
(en)
|
2016-02-08 |
2018-07-26 |
Vitrisa Therapeutics, Inc. |
Compositions with improved intravitreal half-life and uses thereof
|
|
WO2018136831A1
(en)
|
2017-01-20 |
2018-07-26 |
Vitrisa Therapeutics, Inc. |
Pseudoknot compositions and methods for inhibiting factor d
|
|
WO2018136827A1
(en)
|
2017-01-20 |
2018-07-26 |
Vitrisa Therapeutics, Inc. |
Stem-loop compositions and methods for inhibiting factor d
|
|
WO2019022986A1
(en)
|
2017-07-24 |
2019-01-31 |
Vitrisa Therapeutics, Inc. |
NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR
|